



**Review Article**  
*JBS. 2016 June; 3(2):24-28*

# Journal of Biomedical Sciences

## *Official Publication of NHRWS*

### Genetic basis of obesity: a review

Bedanta Roy, Sumitabha Ghosh, Brijesh Sathian, Indrajit Banerjee

- |                    |  |
|--------------------|--|
| <b>References</b>  | This article cites 21 articles some of which you can access for free at Pubmed Central   |
| <b>Permissions</b> | To obtain permission for the commercial use or material from this paper, please write – <a href="mailto:jbs.editors@gmail.com">jbs.editors@gmail.com</a> |

### Cite this Article

Roy B, Ghosh S, Sathian B, Banerjee I. Genetic basis of obesity: a review. Journal of Biomedical Sciences. 2016;3(2):24-28.

**PLEASE SCROLL DOWN TO READ THE ARTICLE**

This article is Open Access and is published under the Creative Commons CC-BY License (<https://creativecommons.org/licenses/by/4.0/>). This license permits use, distribution and reproduction in any medium, provided the original work is properly cited. NHRWS does not give any warranty express or implied or make any representation of the accuracy of the contents or up to date. It (includes - instructions, formulae and drug doses) should be independently verified with all available primary sources. The publisher shall not be legally responsible for any types of loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.



## Genetic basis of obesity: a review

Roy B<sup>1</sup>, Ghosh S<sup>2</sup>, Sathian B<sup>3</sup>, Banerjee I<sup>4</sup>

### *Correspondence to:*

[bedanta.roy@gmail.com](mailto:bedanta.roy@gmail.com)

<sup>1</sup>Dr. Bedanta Roy, Senior Lecturer, Department of Physiology, Faculty of Medicine, QIUP, Ipoh, Malaysia

<sup>2</sup>Prof. Dr. Sumitabha Ghosh, Professor and HOD, Department of Physiology, Faculty of Medicine, QIUP, Ipoh, Malaysia.

<sup>3</sup>Dr. Brijesh Sathian, Academic Research Associate, Trauma Surgery, Hamad General Hospital, Doha, Qatar.

<sup>4</sup>Dr. Indrajit Banerjee, Associate Professor, Department of Pharmacology, Chitwan Medical College and Teaching Hospital, Chitwan, Nepal.

### *Information about the article*

Received: June. 3, 2017

Revised: Sep. 24, 2017

Accepted: Nov. 10, 2017

Published online: Dec. 24, 2017


### ABSTRACT

Obesity is a state of “positive” energy balance when energy intake is much greater than energy expenditure. The familial aggregation of body size was first published by Sir Francis Galton in 1889, which became a well-established risk factor for childhood obesity. Obesity is often allied with insulin resistance, dyslipidemia and cardiovascular disease.

Monogenic obesity includes the involvements of Leptin (LEP) gene, leptin receptor (LEPR), Proopiomelanocortin (POMC), Melanocortin-4 receptor (MC4R), single-minded gene 1 (SIM 1), Proprotein convertase subtilisin/kexin type 1 (PCSK1), Neuropeptide Y (NPY). Polygenic obesity is due to Adrenoceptor beta 1 (ADRB1), ADRB2, ADRB3, Uncoupling protein 1 (UCP1), UCP2, UCP3. Monogenic and polygenic obesity; pleiotropic syndromes, chromosomal rearrangement are different types of obesity with genetic cause. Surprisingly all “obesity genes” carriers do not become overweight, and exercise, maintaining healthy routine is a significant contributing factor to nullify genetic predisposition.

## Background:

Obesity is a state of “positive” energy balance when energy intake is much greater than energy expenditure. Obesity occurs when excess body fat accumulates. It is a well known fact that obesity is associated with cardiovascular disorder (CVD), type 2 diabetes, and cancer. Although environment contributes for the development of obesity, but genetics also plays a crucial role (40% - 70%). The familial aggregation of body size was first published by Sir Francis Galton in 1889, which became a well-established risk factor for childhood obesity. The search for human obesity genes started long back. The search was intensified by the advances in the molecular biology techniques. Genetics influence the normal physiology, embryonic development, adaptation, and obesity. Still the research in “genetic environment interactions” is in the early stage [1, 2].




**Figure – 1 Role of genes in obesity**

Monogenic obesity includes the involvements of Leptin (LEP) gene, leptin receptor (LEPR), Proopiomelanocortin (POMC), Melanocortin-4 receptor (MC4R), single-minded gene 1 (SIM1), Proprotein convertase subtilisin/kexin type 1 (PCSK1), Neuropeptide Y (NPY). Polygenic obesity is due to Adrenoceptor beta 1 (ADRB1), ADRB2, ADRB3, Uncoupling protein 1 (UCP1), UCP2, UCP3. Monogenic obesity occurs due to spontaneous mutations in a single gene, which is relatively rare and on the other side, endocrine disorders are responsible for severe early-onset obesity. Genes control appetite, intake of food, and energy equilibrium in the body. Genes code for hormone leptin, leptin receptor, melanocortin-4 receptor, pro-opiomelanocortin, Melanocortin-4 receptor, Single-minded gene 1, PCSK1 - Proprotein convertase subtilisin/kexin type 1 [3, 4].

### Role of Leptin

The LEP gene produces hormone leptin from adipocytes, regulates body weight. Leptin binds to leptin receptor, found in many organs including hypothalamus, which controls hunger and thirst. Leptin binds with receptor and acts via Janus Kinases-start activators of transcription (JAK-STAT) signaling pathways.



**Figure – 2 Chromosome location: Leptin gene**

It is downstream signaling pathways, inhibit feeding & promote energy expenditure i.e. producing a feeling of fullness (satiety) [5]. The chromosome for leptin is located in 7q32.1, long (q) arm of chromosome 7 at the position 32.1 [6]. Leptin gene and regulatory regions mutation cause severe morbid obesity associated with Hypogonadism [7]. Subcutaneous injection of leptin is clinically recommended in LEP deficient children and adults. It decreases food intake and slower rate of eating which leads to weight loss and decrease in fat mass.

**Table – 1 Rare monogenic forms of human obesity**

Gene	Mutation type	obesity	Associated phenotypes
<b>Leptin (LEP)</b>	Homozygous mutation	Severe, from the first days of life	Gonadotropic and thyrotropic insufficiency
<b>Leptin receptor (LEPR)</b>	Homozygous mutation	Severe, from the first day of life	Gonadotropic, thyrotropic and somatotropic insufficiency
<b>Proopiomelanocortin (POMC)</b>	Homozygous or compound heterozygous mutation	Severe, from the first months of life	ACTH insufficiency Mild hypothyroidism and ginger hairs if the mutation leads to the absence of POMC production
<b>Proprotein convertase subtilisin/kexin type 1 (PCSK1)</b>	Homozygous or compound heterozygous mutation	Severe obesity occurring in childhood	Adrenal, gonadotropic, somatotropic and thyrotropic insufficiency Postprandial hypoglycemic malaises Central diabetes insipidus
<b>Single-minded 1 (SIM1)</b>	Translocation between chr1p22.1 and 6q16.2 in the SIM1 gene	Severe obesity occurring in childhood	Inconstantly, neurobehavioral abnormalities (including emotional lability or autism-like behavior)

Table 1 reveals that rare monogenic forms of human obesity involving Leptin, Leptin receptor, Proopiomelanocortin, Proprotein convertase subtilisin/kexin type 1, Single-minded 1 [8].

### Obesity and Melanocortin 4 receptor (MC4R)

MC4R gene encodes MC4R protein, controls feeding behaviour, metabolism, sexual behaviour, and erectile function in males [9, 10]. In 2009, two very large genome-wide association studies of BMI confirmed the association of variants with insulin resistance, obesity. 2 - 3% of adult and child obesity is associated with MC4R [11-13]. Normally  $\alpha$  melanocyte-stimulating hormone plays a vital role on MC4R, which reduces food intake [14].

It is well documented that mutations or failure in the function of proopiomelanocortin gene causes obesity in experimental models like mice and humans. Carriers of MC4R gene variant (22% of the general population) have both appetite & satiety. Remarkable behavioural changes include eating larger amounts of food, frequent intake of snacks, and more attractions towards fatty foods are common. Research evidences suggests each copy of the variant is responsible for a BMI (Body Mass Index) 0.22 which risks obesity by 8% [15-17].

### Polygenic obesity "common obesity" mutations in multiple genes

Majority (>95% of cases) of the obesity is polygenic obesity, in clinical situations. Each susceptibility gene, contributes a little on weight gain. 'obesogenic lifestyle' increases the risk for cumulative effect from these genes. Obesogenic lifestyle factors includes overfeeding, Sedentariness and stress [8].

Ample evidence available from animal models, human linkage studies, monozygotic and dizygotic twins, and association research works of large populations shows significant contributions in common obesity. Twin studies unfolded the genetics of common obesity. Data obtained from 25,000 twin pairs and 50,000 biological and adoptive family members, showed that mean correlations for BMI (estimated) were 0.74 for monozygotic twins, where as 0.32 was for dizygotic twins [13].

Researchs showed that genes played a significant contribution for BMI of monozygotic twins but in shared genes the effect is relatively less. However, the study assumed that both twins grown up same degree of shared environment.

### Syndromic obesity

Genetic syndromes also contributes obesity. Significantly impaired intellectual and adaptive functioning, dysmorphic features, anomalies in the development is most commonly observed in severe obesity.


### Pleiotropic syndromes

Obesity as a clinical feature is observed in 30 Mendelian disorders [18]. Pleiotropic syndromes occurs when one gene influences two or more apparently unrelated

phenotypic traits. Some of the common examples are Albright's hereditary osteodystrophy syndrome, Alström syndrome, Bardet-Biedl syndrome, Borjeson, Forssman and Lehmann syndrome, Cohen syndrome, Fragile X syndrome, Mehmo syndrome, Simpson-Golabi-Behmel syndrome, Ulnar-mammary syndrome, Wilson-Turner syndrome. Chromosomal rearrangements involves obesity include Prader-Willi syndrome, Sim-1 [single-minded (Sim) gene], WAGR syndrome[4].

### "Fat mass and obesity-associated" (FTO) gene

It is located in chromosome 16. This gene is associated with appetite in humans. "High-risk" FTO variants are the most susceptible with an increase in age. There is an 20-30% increase obesity risk for the variants. A specific high-risk variant is rs1421085. Fat mass and obesity-associated protein is an enzyme (encoded by the FTO gene), identified in 2007 [12, 13]. It has been observed that high-fat food is a preferable choice for its carriers. They become obese with advance in age [19].



**Figure - 3 Proposed mechanism of action of FTO in controlling obesity**

Although human genes have not changed more but rising obesity cases may be a result of changed environmental factors - physical, social, political, economic surroundings. These factors determines our physical activity, food habit and eating behavior causes the recent surge of overweight and obesity [18]. Research showed physically active individuals can counterbalance the effects of one obesity-promoting gene (FTO variant) [20, 21].

## Conclusion

Genes control obesity. Monogenic and polygenic obesity; pleiotropic syndromes, chromosomal rearrangement are different types. Surprisingly all “obesity genes” carriers do not become overweight, and exercise, maintaining healthy routine is a significant contributing factor to nullify genetic predisposition. Some people have single gene disorders of obesity (rare forms; <1% of the obesity cases). In the same environment different people have different risk of obesity including genetic influences on food preference, food addiction, pleasurable feelings from food and exercise. So according to scientist Veerman, “genes may co-determine who becomes obese, but our environment determines how many become obese.”

## Competing interests

None declared.

## Authors' contribution

BR and SG drafted the manuscript. BS and IB critically revised, incorporated necessary changes. Final manuscript is approved by all authors.

## Abbreviations

Adrenoceptor beta 1 (ADRB1), cardiovascular disorder (CVD), Janus Kinases-start activators(JAK-STAT), Leptin (LEP) gene, leptin receptor(LEPR), Melanocortin-4 receptor (MC4R), Neuropeptide Y (NPY), Proopiomelanocortin (POMC), Proprotein convertase subtilisin/ kexin type 1 (PCSK1), single-minded gene 1 (SIM 1), Uncoupling protein 1(UCP1).

## References

1. Qi Q, Chu AY, Kang JH, Huang J, Rose LM, Jensen MK. Fried food consumption, genetic risk, and body mass index: gene-diet interaction analysis in three US cohort studies. *BMJ*.2014;19;348:g1610.
2. Shawky RM, Sadik DI. Genetics of obesity. *Egyptian Journal of Medical Human Genetics*.2012; 13(1):11-17
3. Hu FB. Genetic predictors of obesity. Part III Epidemiologic Studies of Determinants of Obesity. *Obesity epidemiology*. Oxford University Press; 2008. 498 p.
4. Farooqi S, O'Rahilly S. Genetics of obesity in humans. *Endocr Rev*. 2006; 27:710-18.
5. NCBI. LEP leptin [ Homo sapiens (human) ]. Gene ID: 3952. [Cited on 21-12-2017]. Available from <https://www.ncbi.nlm.nih.gov/gene/3952>
6. Yeo GSH. Food Intake, Circuitry, and Energy Metabolism. In: *Molecular Neuroendocrinology*. Chichester, UK: John Wiley & Sons, Ltd; 2016. p. 355–73.
7. Farooqi IS, O'Rahilly S. New advances in the genetics of early onset obesity. *Int J Obes (Lond)*. 2005;29(10):1149-52.
8. Huvenne H, Dubern B. Monogenic Forms of Obesity. In: *Molecular Mechanisms Underpinning the Development of Obesity*. Cham: Springer International Publishing; 2014. p. 9–21.
9. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. *Nature*. 1997;385(6612):165-8.
10. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell*. 1997 Jan 10;88(1):131-41.
11. Thorleifsson G, Walters GB, Gudbjartsson DF, Steinthorsdottir V, Sulem P, Helgadóttir A, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nat Genet*. 2009;41(1):18-24.
12. Willer CJ, Speliotes EK, Loos RJ, Li S, Lindgren CM, Heid IM et al. Genetic Investigation of ANthropometric Traits Consortium. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. *Nat Genet*. 2009;41(1):25-34.
13. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body weight and human adiposity. *Behav Genet*. 1997; 27:325-51.
14. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med*. 2003 Mar 20;348(12):1085-95.
15. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. *Nat Med* 1999;5:1066-1070.
16. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. *Nat Genet* 1998;19:155-7

17. Yeo GS, Farooqi IS, Challis BG, Jackson RS, O'Rahilly S. The role of melanocortin signaling in the control of body weight: evidence from human and murine genetic models. *QJM* 2000;93:7-14
18. Qi L, Cho YA. Gene-environment interaction and obesity. *Nutr Rev.* 2008; 66:684-94.
19. NHS. FTO 'fat gene' may make people more impulsive. [Cited on 18-09-2017]. Available from <https://www.nhs.uk/news/genetics-and-stem-cells/fto-fat-gene-may-make-people-more-impulsive/>
20. Andreasen CH, Stender-Petersen KL, Mogensen MS, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. *Diabetes.* 2008; 57:95-101.
21. Kilpeläinen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. *PLoS Med.* 2011;8:e1001116.